On November 6th, Suzhou Linaxin Biotechnology Co., Ltd. and Jiangsu Kangmeng Holdings Group Co., Ltd. (hereinafter referred to as "Kangmeng Holdings") signed a cooperation agreement to jointly promote and popularize early screening for colorectal cancer. Through the integration of IoT technology and a new model of health sharing, they will jointly create a shared health technology industry ecosystem, allowing residents to achieve self testing of intestinal health.

Kangmeng Holdings Group is a new type of group company that integrates health management, medical equipment, shared health equipment, human health data, and the Internet of Things. Through this cooperation, Kangmeng Holdings will promote millions of domestic home self testing fecal occult blood (Changlexin), transferrin (Changweile), and FOB combined multi gene variant fecal colon cancer early screening (Lichangsheng) detection products under Linaxin Biotechnology to millions of households, and provide a one-stop intestinal health early screening solution of "screening education and training+early screening products+health management".